X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6565) 6565
female (4275) 4275
male (3811) 3811
middle aged (3668) 3668
cancer (3488) 3488
oncology (3372) 3372
aged (3345) 3345
prognosis (3038) 3038
pancreatic cancer (2578) 2578
carcinoma (2421) 2421
surgery (2366) 2366
adult (2313) 2313
pancreatic neoplasms - pathology (2251) 2251
metastasis (2017) 2017
tumors (1923) 1923
pancreatic neoplasms - mortality (1833) 1833
survival (1817) 1817
adenocarcinoma (1731) 1731
aged, 80 and over (1587) 1587
pancreatic neoplasms - surgery (1488) 1488
expression (1476) 1476
carcinoma, pancreatic ductal - pathology (1352) 1352
medical prognosis (1335) 1335
analysis (1324) 1324
retrospective studies (1256) 1256
immunohistochemistry (1238) 1238
gastroenterology & hepatology (1216) 1216
carcinoma, pancreatic ductal - mortality (1214) 1214
neoplasm staging (1211) 1211
chemotherapy (1205) 1205
survival rate (1171) 1171
gene expression (1170) 1170
research (1157) 1157
medicine & public health (1128) 1128
animals (1083) 1083
proteins (1072) 1072
cell line, tumor (1003) 1003
health aspects (990) 990
treatment outcome (983) 983
survival analysis (961) 961
care and treatment (958) 958
pathology (918) 918
mortality (902) 902
development and progression (900) 900
pancreaticoduodenectomy (890) 890
carcinoma, pancreatic ductal - surgery (881) 881
pancreas (868) 868
breast cancer (851) 851
kaplan-meier estimate (824) 824
apoptosis (822) 822
diagnosis (812) 812
risk factors (781) 781
patients (780) 780
genetic aspects (777) 777
pancreatic neoplasms - genetics (773) 773
gene expression regulation, neoplastic (754) 754
biomarkers (750) 750
cancer therapies (705) 705
ductal adenocarcinoma (697) 697
metastases (697) 697
cell biology (689) 689
pancreatic neoplasms - metabolism (686) 686
neoplasm invasiveness (683) 683
resection (669) 669
mice (659) 659
studies (659) 659
follow-up studies (658) 658
cell proliferation (645) 645
breast-cancer (637) 637
lymphatic metastasis (619) 619
multivariate analysis (614) 614
adenocarcinoma - pathology (608) 608
carcinoma, pancreatic ductal - genetics (586) 586
biomarkers, tumor - metabolism (579) 579
kinases (578) 578
disease-free survival (562) 562
gemcitabine (553) 553
research article (550) 550
hepatocellular-carcinoma (542) 542
pancreatic neoplasms - diagnosis (541) 541
adenocarcinoma - mortality (536) 536
invasion (534) 534
medicine (531) 531
medical research (521) 521
pancreatectomy (520) 520
proportional hazards models (515) 515
carcinoma, pancreatic ductal - metabolism (513) 513
signal transduction (506) 506
progression (501) 501
pancreatic neoplasms - drug therapy (497) 497
gastroenterology (489) 489
pancreatic ductal adenocarcinoma (486) 486
pancreatic neoplasms - therapy (484) 484
cancer research (483) 483
abridged index medicus (475) 475
mutation (474) 474
growth (469) 469
colorectal cancer (462) 462
disease progression (462) 462
multidisciplinary sciences (462) 462
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8106) 8106
German (80) 80
Japanese (22) 22
French (12) 12
Spanish (11) 11
Chinese (6) 6
Czech (5) 5
Korean (5) 5
Portuguese (4) 4
Italian (3) 3
Norwegian (3) 3
Russian (3) 3
Danish (1) 1
Hungarian (1) 1
Polish (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2015, Volume 21, Issue 11, pp. 1364 - 1371
Journal Article
Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 5, pp. 497 - 505
Journal Article
Journal Article
Pancreas, ISSN 0885-3177, 07/2015, Volume 44, Issue 5, pp. 693 - 712
Journal Article
Journal Article
Cancer discovery, ISSN 2159-8274, 08/2016, Volume 6, Issue 8, pp. 870 - 885
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a low 5-year survival rate, yet new immunotherapeutic modalities may offer hope for this and other intractable cancers... 
CELLS | ACTIVATION | PI3K | ONCOLOGY | MICE | INHIBITOR | CANCER | TUMOR INFLAMMATION | GEMCITABINE | DISCOVERY | CHECKPOINT BLOCKADE | Macrophage Activation - genetics | Pancreatic Neoplasms - metabolism | Class Ib Phosphatidylinositol 3-Kinase - genetics | Humans | Carcinoma, Pancreatic Ductal - metabolism | Male | Platelet-Derived Growth Factor - genetics | Cell Movement - genetics | Carcinoma, Pancreatic Ductal - genetics | Neoplasm Metastasis | Heterografts | Class Ib Phosphatidylinositol 3-Kinase - metabolism | Antineoplastic Agents - pharmacology | Carcinoma, Pancreatic Ductal - immunology | Macrophages - immunology | Disease Models, Animal | Phenols - pharmacology | Gene Expression | Pteridines - pharmacology | Immunomodulation | Macrophage Activation - immunology | Mortality | Pancreatic Neoplasms - pathology | Mice, Transgenic | Pancreatic Neoplasms - genetics | Gene Knockout Techniques | Carcinoma, Pancreatic Ductal - pathology | Disease Progression | Mice, Knockout | Xenograft Model Antitumor Assays | Macrophages - metabolism | Platelet-Derived Growth Factor - metabolism | Animals | Pancreatic Neoplasms - immunology | Biomarkers | Cell Line, Tumor | Mice | Class Ib Phosphatidylinositol 3-Kinase - antagonists & inhibitors | macrophages | transcription | desmoplasia | metastasis | PDGF | Arginase | gemcitabine | PI3Kγ | immune suppression | chemotherapy | pancreatic ductal adenocarcinoma
Journal Article
Drug resistance updates, ISSN 1368-7646, 2015, Volume 23, pp. 55 - 68
Abstract Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths... 
Infectious Disease | Hematology, Oncology and Palliative Medicine | Gemcitabine | Environment mediated drug resistance | Metabolism | Pancreatic ductal adenocarcinoma | Chemoresistance | PHARMACOLOGY & PHARMACY | MicroRNAs - antagonists & inhibitors | Apoptosis - drug effects | Humans | Gene Expression Regulation, Neoplastic | Apoptosis - genetics | MicroRNAs - metabolism | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasm Proteins - metabolism | Carcinoma, Pancreatic Ductal - genetics | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Carcinoma, Pancreatic Ductal - mortality | MicroRNAs - agonists | Pancreatic Neoplasms - mortality | Neoplasm Proteins - genetics | Tumor Microenvironment - drug effects | Signal Transduction | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - pathology | Enzyme Inhibitors - therapeutic use | Carcinoma, Pancreatic Ductal - drug therapy | Drug Resistance, Neoplasm - genetics | Ribonucleotide Reductases - antagonists & inhibitors | Ribonucleotide Reductases - metabolism | Survival Analysis | MicroRNAs - genetics | Ribonucleotide Reductases - genetics | Deoxycytidine - analogs & derivatives | Drug Resistance, Neoplasm - drug effects | Adenocarcinoma | Chemotherapy | Drug resistance | Cancer | Medical research | Pancreatic cancer | Medicine, Experimental | Rankings | Metastasis
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10039, pp. 73 - 85
Summary Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence... 
Internal Medicine | PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | DIFFERENTIAL-DIAGNOSIS | FINE-NEEDLE-ASPIRATION | INCREASED RISK | AUTOIMMUNE PANCREATITIS | EARLY MANIFESTATIONS | CLASSIFICATION-SYSTEM | PREOPERATIVE EVALUATION | INTRAEPITHELIAL NEOPLASIA | Leucovorin - administration & dosage | Endosonography | Pancreatic Neoplasms - diagnosis | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Tumor Suppressor Protein p53 - genetics | Carcinoembryonic Antigen - metabolism | Carcinoma, Pancreatic Ductal - genetics | Neoplasms, Cystic, Mucinous, and Serous - genetics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Smad4 Protein - genetics | Carcinoma, Pancreatic Ductal - diagnosis | Camptothecin - administration & dosage | Paclitaxel - administration & dosage | Endoscopic Ultrasound-Guided Fine Needle Aspiration | Camptothecin - analogs & derivatives | Deoxycytidine - administration & dosage | Pancreatectomy | Albumins - administration & dosage | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - therapy | Genes, p16 | CA-19-9 Antigen - metabolism | Neoplasms, Cystic, Mucinous, and Serous - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Cystic, Mucinous, and Serous - diagnosis | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Medical colleges | Ultrasound imaging | Oncology, Experimental | Mortality | Japan | Pancreatitis | Adjuvant treatment | Leucovorin | Research | Pancreatic cancer | Diagnosis | Tumor proteins | Health aspects | Cancer | Pathology | Chemotherapy | Medical prognosis | Metastasis | Health risk assessment | Cancer therapies | Tumors
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 1/2007, Volume 14, Issue 1, pp. 118 - 127
Journal Article
Cancer letters, ISSN 0304-3835, 2019, Volume 442, pp. 333 - 340
Journal Article